Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review

Introduction Baricitinib has shown positive results in clinical trials both from efficacy and safety outcomes; however, there is still a need to further understand its use in routine practice in Spain. Methods This observational study aimed to describe treatment patterns, persistence, and effectiven...

Descripción completa

Detalles Bibliográficos
Autores: de la Fuente, EG, Herrera, E, Esquerdo, IME, Sarró, DV, Figueras-Nart, I, Salvador, JFS, Gilaberte, Y, Alarcón, SS, Serra-Baldrich, E, Campos, MM, Moro, RM, Díaz-Cerezo, S, Moyano, S, Talavera-Rodríguez, I, Núñez, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:dnet:r-fisabio___::432d2c80cfc782bb68b5dffd55c7322c
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/21268
Access Level:acceso abierto
Palabra clave:Atopic dermatitis
Baricitinib
Real-world
Spain
id ES_49ed8abff1d37b76f17e6f705e68fc8e
oai_identifier_str oai:dnet:r-fisabio___::432d2c80cfc782bb68b5dffd55c7322c
network_acronym_str ES
network_name_str España
repository_id_str
spelling Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Reviewde la Fuente, EGHerrera, EEsquerdo, IMESarró, DVFigueras-Nart, ISalvador, JFSGilaberte, YAlarcón, SSSerra-Baldrich, ECampos, MMMoro, RMDíaz-Cerezo, SMoyano, STalavera-Rodríguez, INúñez, MAtopic dermatitisBaricitinibReal-worldSpainIntroduction Baricitinib has shown positive results in clinical trials both from efficacy and safety outcomes; however, there is still a need to further understand its use in routine practice in Spain. Methods This observational study aimed to describe treatment patterns, persistence, and effectiveness of baricitinib among adult patients with atopic dermatitis (AD) in Spain. A retrospective chart review was carried out in 13 hospitals across Spain. Effectiveness was described using the Eczema Area and Severity Index (EASI), the Investigator's Global Assessment (IGA), and the Itch and Sleep numerical rating scales (NRS) recorded as part of routine clinical practice. Persistence to treatment was estimated using Kaplan-Meier curves. Results Seventy-four patients were included and followed for a mean of 42.1 (standard deviation, SD 21.4) weeks. At baseline, over half of the patients had severe AD, with an EASI > 21 (63%) and an IGA-4 (56.8%). Patients had received a mean of 2.4 (SD 1.2) prior systemic treatments and were prescribed baricitinib mainly due to lack of effectiveness of previous treatment. Most patients were prescribed baricitinib as the sole systemic treatment for AD and did not receive any other systemic treatment during the follow-up. During the study period, 39.2% of patients discontinued baricitinib, mainly due to lack of effectiveness. At week 16, 69.7% of patients who remained on treatment and had a measurement available achieved a >= 75% improvement from baseline in the EASI (EASI75) response and 79.3% an IGA score of 0 or 1. Conclusions Among patients who remained on treatment, baricitinib showed meaningful clinical improvements in routine clinical practice in Spain. Our findings highlight rapid and sustained clinical improvements, aligning with that observed in other real-world studies. Infographic available for this article.ADIS INT LTD2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/21268Dermatology and TherapyISSN: 21938210ISSNe: 21909172reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:dnet:r-fisabio___::432d2c80cfc782bb68b5dffd55c7322c2026-06-11T12:45:17Z
dc.title.none.fl_str_mv Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
title Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
spellingShingle Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
de la Fuente, EG
Atopic dermatitis
Baricitinib
Real-world
Spain
title_short Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
title_full Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
title_fullStr Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
title_full_unstemmed Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
title_sort Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
dc.creator.none.fl_str_mv de la Fuente, EG
Herrera, E
Esquerdo, IME
Sarró, DV
Figueras-Nart, I
Salvador, JFS
Gilaberte, Y
Alarcón, SS
Serra-Baldrich, E
Campos, MM
Moro, RM
Díaz-Cerezo, S
Moyano, S
Talavera-Rodríguez, I
Núñez, M
author de la Fuente, EG
author_facet de la Fuente, EG
Herrera, E
Esquerdo, IME
Sarró, DV
Figueras-Nart, I
Salvador, JFS
Gilaberte, Y
Alarcón, SS
Serra-Baldrich, E
Campos, MM
Moro, RM
Díaz-Cerezo, S
Moyano, S
Talavera-Rodríguez, I
Núñez, M
author_role author
author2 Herrera, E
Esquerdo, IME
Sarró, DV
Figueras-Nart, I
Salvador, JFS
Gilaberte, Y
Alarcón, SS
Serra-Baldrich, E
Campos, MM
Moro, RM
Díaz-Cerezo, S
Moyano, S
Talavera-Rodríguez, I
Núñez, M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Atopic dermatitis
Baricitinib
Real-world
Spain
topic Atopic dermatitis
Baricitinib
Real-world
Spain
description Introduction Baricitinib has shown positive results in clinical trials both from efficacy and safety outcomes; however, there is still a need to further understand its use in routine practice in Spain. Methods This observational study aimed to describe treatment patterns, persistence, and effectiveness of baricitinib among adult patients with atopic dermatitis (AD) in Spain. A retrospective chart review was carried out in 13 hospitals across Spain. Effectiveness was described using the Eczema Area and Severity Index (EASI), the Investigator's Global Assessment (IGA), and the Itch and Sleep numerical rating scales (NRS) recorded as part of routine clinical practice. Persistence to treatment was estimated using Kaplan-Meier curves. Results Seventy-four patients were included and followed for a mean of 42.1 (standard deviation, SD 21.4) weeks. At baseline, over half of the patients had severe AD, with an EASI > 21 (63%) and an IGA-4 (56.8%). Patients had received a mean of 2.4 (SD 1.2) prior systemic treatments and were prescribed baricitinib mainly due to lack of effectiveness of previous treatment. Most patients were prescribed baricitinib as the sole systemic treatment for AD and did not receive any other systemic treatment during the follow-up. During the study period, 39.2% of patients discontinued baricitinib, mainly due to lack of effectiveness. At week 16, 69.7% of patients who remained on treatment and had a measurement available achieved a >= 75% improvement from baseline in the EASI (EASI75) response and 79.3% an IGA score of 0 or 1. Conclusions Among patients who remained on treatment, baricitinib showed meaningful clinical improvements in routine clinical practice in Spain. Our findings highlight rapid and sustained clinical improvements, aligning with that observed in other real-world studies. Infographic available for this article.
publishDate 2026
dc.date.none.fl_str_mv 2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/21268
url https://fisabio.portalinvestigacion.com/publicaciones/21268
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ADIS INT LTD
publisher.none.fl_str_mv ADIS INT LTD
dc.source.none.fl_str_mv Dermatology and Therapy
ISSN: 21938210
ISSNe: 21909172
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407454433902592
score 15,812455

Similares en LA Referencia